Inclusion Criteria:

- ≥ 18 years of age.

- Histologically confirmed diagnosis of glioblastoma after initial tumor resection with
radiographic evidence of recurrent tumor per RANO criteria.

- Documented evidence of PTEN mutations, homozygous deletion of PTEN or PTEN negative
by IHC confirmed by local or central assessment

- Must have received the following treatment for glioblastoma:

- Prior adjuvant treatment with radiotherapy and temozolomide;

- A maximum of two prior chemotherapy regimens (including bevacizumab or other
direct VEFG/VEGFR inhibitors) for recurrent disease are permitted.

- Representative archival or newly obtained tumor sample from glioblastoma
(formalin-fixed paraffine embedded tissue) must be available.

- ECOG performance status ≥ 2.

- Able to swallow and retain oral medication.

- Patients in the surgical arm only: patients with recurrent glioblastoma must be
eligible for surgical resection as deemed by the site Investigator.

Exclusion Criteria:

- Prior or current treatment with a c-MET inhibitor or HGF-targeting therapy

- Prior treatment with a PI3K and/or mTOR inhibitors for glioblastoma

- Received radiation (including therapeutic radioisotopes such as strontium 89)
therapy ≤ 4 weeks prior to the first dose of study treatment and have not recovered
from side effects of such therapy (≤ Grade 1) prior to the first dose of study
treatment, except for alopecia.

- Currently being treated with Enzyme Inducing Anti-Epileptic Drug (EIAED). If
previously on an EIAED, the patient must be off of it for at least 2 weeks prior to
study treatment.

- Currently receiving warfarin or other coumadin-derived anticoagulants for treatment,
prophylaxis or otherwise.

- Currently receiving increasing or chronic treatment ( > 5 days) with corticosteroids
or another immunosuppressive agent.

- History of acute or chronic pancreatitis or any risk factors that may increase the
risk of pancreatitis.

- Active cardiac disease or a history of cardiac dysfunction.

- Impairment of gastrointestinal (GI) function or GI disease that might significantly
alter the absorption of study drug

- Medically documented history of or active major depressive episode, bipolar disorder
(I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal
attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or
others), or patients with active severe personality disorders (defined according to
DSM- IV).

- Anxiety ≥ CTCAE grade 3

- Any of the following baseline laboratory values:

- Hemoglobin < 9 g/dL

- Platelet count < 75 x 109/L

- Absolute neutrophil count (ANC) < 1.0 x 109/L

- INR > 1.5

- Serum lipase > normal limits for the institution

- Asymptomatic serum amylase > grade 2

- Potassium, magnesium, and calcium (corrected for albumin) > normal limits for
the institution

- Total bilirubin ≥2 x upper limit of normal (ULN)

- Serum creatinine >1.5 x ULN or creatinine clearance ≤ 45 mL/min

- Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > normal
range (or < 3.0 x ULN if liver metastases are present)

- Fasting plasma glucose > 120mg/dL or > 6.7 mmol/L

- HbA1c > 8%.